Page last updated: 2024-10-25

cloxyquin and Benign Neoplasms

cloxyquin has been researched along with Benign Neoplasms in 2 studies

cloxyquin: has antitubercular activity; structure in first source

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Lin, R1
Elf, S1
Shan, C1
Kang, HB1
Ji, Q1
Zhou, L1
Hitosugi, T1
Zhang, L1
Zhang, S1
Seo, JH1
Xie, J1
Tucker, M1
Gu, TL1
Sudderth, J1
Jiang, L1
Mitsche, M1
DeBerardinis, RJ1
Wu, S1
Li, Y1
Mao, H1
Chen, PR1
Wang, D1
Chen, GZ1
Hurwitz, SJ1
Lonial, S1
Arellano, ML1
Khoury, HJ1
Khuri, FR1
Lee, BH1
Lei, Q1
Brat, DJ1
Ye, K1
Boggon, TJ1
He, C1
Kang, S1
Fan, J1
Chen, J1
Pape, VFS1
Palkó, R1
Tóth, S1
Szabó, MJ1
Sessler, J1
Dormán, G1
Enyedy, ÉA1
Soós, T1
Szatmári, I1
Szakács, G1

Reviews

1 review available for cloxyquin and Benign Neoplasms

ArticleYear
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
    Nature cell biology, 2015, Volume: 17, Issue:11

    Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms;

2015

Other Studies

1 other study available for cloxyquin and Benign Neoplasms

ArticleYear
Structure-Activity Relationships of 8-Hydroxyquinoline-Derived Mannich Bases with Tertiary Amines Targeting Multidrug-Resistant Cancer.
    Journal of medicinal chemistry, 2022, 06-09, Volume: 65, Issue:11

    Topics: Antineoplastic Agents; Chelating Agents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Human

2022